Saturday 17 October 2026 Export LYRA’s income statement to Excel — free account

Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $398,000.00, down 74.1% from fiscal 2024. In the quarter to December 2025, revenue fell 96.7%, EPS grew 53.0% and free cash flow grew 45.4%, each against the same quarter a year earlier.

0.19 0.00 0.00%

Follow LYRA

Alert me

Market cap: $870.0K
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 3/9
Altman Z: −19.35
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.54

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	2	—	—	—	—	—	—	—	—	—

Insider Ownership 76.18%

Capital & Financial Ratios $m

Market Cap 0.87

Revenue 0.40

Net Income (28.92)

Free Cash Flow (28.90)

Net Debt (15.89)

Current Ratio 1.71

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.07)

P/S ratio 0.74

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 97.90%

Next Y EPS Growth 34.00%

Next Y revenue growth 75.88%

Next 5Y EPS Growth 53.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.76%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	98	103	41	16
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	101	105	43	16

	2022	2023	2024	2025
Payables	3	3	1	1
ST’ Debt	—	—	—	—
Other	8	—	4	3
	14	20	13	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	(20.38%)	(33.66%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	0	0	0	0
’24	1	1	0	0	2
’23	0	0	1	0	2
’22	0	1	0	0	1
’21	—	—	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(9)	(7)	(7)	(6)	(29)
’24	(22)	(20)	(16)	(11)	(70)
’23	(16)	(14)	(14)	(19)	(63)
’22	(12)	(8)	(11)	(12)	(43)
’21	(8)	3	(10)	(11)	(26)
’20	(4)	(7)	(4)	(6)	(21)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(9)	(7)	(7)	(6)	(29)
’24	(25)	(20)	(16)	(11)	(72)
’23	(16)	(14)	(14)	(20)	(64)
’22	(12)	(8)	(11)	(12)	(44)
’21	(9)	3	(11)	(12)	(29)
’20	(4)	(8)	(4)	(7)	(23)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	(6.50)	(5.51)	(3.38)	(3.76)	(18.62)
’24	(17.50)	(37.00)	(9.00)	(8.00)	(71.50)
’23	(22.00)	(18.00)	(13.50)	(11.00)	(63.00)
’22	(45.78)	(21.50)	(20.00)	(18.00)	(91.50)
’21	(30.00)	(42.50)	(42.50)	(52.50)	(167.50)
’20	(935.00)	(28.00)	(24.50)	(23.00)	(129.50)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	438.01	195.50	117.50	93.00	8.13	2.84	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	1,100.00	825.00	409.00	275.00	339.50	37.50
People
People	Employees	—	—	—	34	38	53	58	88	30	27
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.01	0.02	0.02	0.05	0.01
Income, $m
Income, $m	Revenue	—	—	1	—	—	0	1	2	2	0
	Gross margin, %	—	—	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(6)	(16)	(22)	(44)	(55)	(63)	(93)	(29)
	EBT margin, %	—	—	(484.65)	0.00	0.00	(15,267.72)	(4,054.66)	(4,019.32)	(6,088.40)	(7,263.32)
	Net income	—	0	(6)	(16)	(22)	(44)	(55)	(63)	(93)	(29)
	Depreciation	—	—	0	0	0	1	1	(3)	(2)	0
Per share, $
Per share, $	Revenue	—	—	0.10	0.00	0.00	1.10	2.25	1.56	1.18	0.26
	Earnings	—	—	(0.47)	(4,036.14)	(129.50)	(167.50)	(91.50)	(63.00)	(71.50)	(18.62)
	Cash flow	—	—	(0.51)	(3,438.50)	(123.07)	(99.42)	(71.75)	(63.55)	(53.77)	(18.58)
	Capex	—	—	0.00	(52.75)	(10.33)	(13.03)	(0.27)	(1.05)	(1.80)	(0.06)
	Free cash flow	—	—	(0.51)	(3,491.25)	(133.40)	(112.46)	(72.02)	(64.60)	(55.57)	(18.65)
	Book value	—	—	1.80	1,832.00	433.60	132.14	133.54	89.77	8.90	(6.90)
	Shares, m	—	—	13	0	0	0	1	1	1	2
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	0.00	—	—	0.00	68.54	166.23	8.76	12.02
	P/B	—	—	0.00	—	—	1.65	1.16	2.90	1.16	0.00
	EV/Sales	—	—	0.00	—	—	0.00	(3.28)	100.28	(17.69)	(27.91)
	EV/FCF	—	—	2.07	—	—	(0.37)	0.10	(2.43)	0.38	0.38
Cash, $m
Cash, $m	Operating cash flow	—	—	(7)	(14)	(21)	(26)	(43)	(63)	(70)	(29)
	Capex	—	—	0	0	(2)	(3)	0	(1)	(2)	0
	Free cash flow	—	—	(7)	(14)	(23)	(29)	(44)	(64)	(72)	(29)
Balance, $m
Balance, $m	Working capital	—	—	23	5	71	30	86	85	30	7
	Total debt	—	—	—	3	2	1	4	—	—	—
	Net debt	—	—	(24)	(10)	(75)	(46)	(98)	(103)	(41)	(16)
	Shareholders’ equity	—	—	23	7	74	34	81	89	12	(11)
Returns, %
Returns, %	ROA	—	—	(48.19)	(80.88)	(46.20)	(64.13)	(67.07)	(49.63)	(89.43)	(56.45)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	5.30	14.15	90.60	(79.98)	(96.08)	(73.67)	(184.99)	(6,594.98)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	−12.97% (below 0%: shrinking)	—	0.00%	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%	Compare
CRIS Curis, Inc.	$1.1M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
MNTRQ 9 Meters Biopharma, Inc.	$1.0M	— (loss-making)	—	−25.99% (below 0%: shrinking)	n/m	+0.01% (above 0%: growing)	0.00%	0.00%	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	— (loss-making)	—	—	n/m	+54.91% (above 0%: growing)	0.00%	0.00%	Compare
LYRA Lyra Therapeutics, Inc.	$870.0K	— (loss-making)	— (loss-making)	−96.65% (below 0%: shrinking)	n/m	+45.44% (above 0%: growing)	100.00%	(101,685.71%)
BTTX Better Therapeutics, Inc.	$850.0K	— (loss-making)	—	—	n/m	+20.43% (above 0%: growing)	0.00%	0.00%	Compare
SEELQ Seelos Therapeutics, Inc.	$700.0K	— (loss-making)	— (loss-making)	+11.90% (above 0%: growing)	n/m	+83.54% (above 0%: growing)	100.00%	(834.84%)	Compare
ATXI Avenue Therapeutics, Inc.	$680.0K	— (loss-making)	— (loss-making)	—	n/m	−169.89% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.0M	—	—	−25.99%	—	+10.22%	0.00%	0.00%

All 614 Biotechnology stocks →

Lyra Therapeutics, Inc. (LYRA) key facts

Concern: Lyra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $398,000.00, down 74.1% from fiscal 2024.
Lyra Therapeutics, Inc. (LYRA) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, LYRA traded at $0.19, a market capitalization of $870,000.00.
Return on equity was −6,595.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −19.35 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.